CN104189288B - A kind of Chinese medicine composition for treating myocardial infarction and its application - Google Patents
A kind of Chinese medicine composition for treating myocardial infarction and its application Download PDFInfo
- Publication number
- CN104189288B CN104189288B CN201410471854.8A CN201410471854A CN104189288B CN 104189288 B CN104189288 B CN 104189288B CN 201410471854 A CN201410471854 A CN 201410471854A CN 104189288 B CN104189288 B CN 104189288B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- myocardial infarction
- medicine composition
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of Chinese medicines, it is related to a kind of Chinese medicine composition, more particularly to a kind of Chinese medicine composition for treating myocardial infarction and its preparation prevention or the application for the treatment of myocardial infarction medicine.Chemotherapeutic agent hepatotoxicity wind agitation for current myocardial infarction is larger, a kind of Chinese medicine composition for treating or preventing myocardial infarction of offer of the invention, and it includes the component of following parts by weight：15 parts of pseudo-ginseng, 6 parts of akebi, 10 parts of the bark of eucommia, 10 parts of wilsonii, 10 parts of Ligusticum wallichii, 20 parts of cattail pollen, 20 parts of lotus nut, 10 parts of Poria cocos, 5 parts of the root of herbaceous peony, 5 parts of ginkgo leaf, 10 parts of radix glycyrrhizae, 8 parts of the coptis, 12 parts of the root of kudzu vine, 12 parts of the root of bidentate achyranthes.The Chinese medicine composition is respectively provided with good therapeutic effect in terms of myocardial infarction is treated, with significant clinical generalization value.
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of Chinese medicine composition and its application, and in particular to one kind treats myocardium stalk
Dead Chinese medicine composition and its application as myocardial infarction medicine.
Background technology
Myocardial infarction is that coronary artery is acute, the myocardial necrosis caused by continuation hypoxic-ischemic.It is clinically to have acutely more
And lasting retrosternal pain, rest and nitrate esters medicine are unable to complete incidence graph, increase with serum enzyme activities and enter
Row ECG Change, can complicated by arrhythmia, shock or heart failure, often can threat to life.This disease is most common in America and Europe, beautiful
State there are about 1,500,000 people and occurs myocardial infarction every year.China is in obvious ascendant trend in recent years, and few 500,000 are newly sent to every year, is now suffered from
At least 2,000,000.Clinician is studying sick pathogenesis etiology discovery, and patient is mostly occurred basic in coronary atherosclerosis
On, because some inducements cause Atherosclerotic Vessels: Changes Observed during Coronary to rupture, the blood platelet in blood is assembled in the plaque surface of rupture, is formed
Clot (thrombus), unexpected blocked coronary arteries tube chamber, causes myocardial ischemia and necrosis；In addition, myocardial oxygen consumption acutely increases or is preced with
Shape arteriospasm can also induce acute myocardial infarction AMI.
At present, the medicine for the treatment of myocardial infarction has：1) beta-blocker；2) angiotensin receptor antagonist (ARB)
With angiotensin converting enzyme inhibitor (ACEI)；3) statins：Its improve remodeling ventricle mechanism of action may be：①
Improve function of vascular endothelium, prevent structural change.2. the concentration and activity of Angiotensin-Converting are reduced, vasotonia is reduced
The generation of element II.3. the expression of angiotensin-ii-receptor is adjusted.4. antioxidation.5. insulin resistance is improved.4) aldehyde is solid
Ketone antagonist.5) endothelin-receptor antagonists；6) Chinese medicine：Shenmai injection, GEGEN ZHUSHEYE, compound danshen dripping pills, the Radix Astragali, pellet
Ginseng etc..
Chinese medicine atherosclerosis have accumulated certain experience, under the guidance of diagnosis and treatment based on an overall analysis of the illness and the patient's condition principle, the differentiation of disease
It is combined with dialectical, both with tcm characteristic, modern medicine pharmacological research achievement, compared with Western medicine, Chinese medicine is combined again
This disease, it is not only evident in efficacy, and without bad toxic side effect, thus with certain advantage.
As CN101229314A discloses a kind of Chinese medicine preparation for treating myocardial infarction induced by myocardial ischemia, its raw material composition
Including：Ginseng, the water frog, the fruit of Chinese magnoliavine, monkshood, the red sage root, the seed of Oriental arborvitae, gadfly, the tuber of pinellia, pseudo-ginseng, Ligusticum wallichii, Moschus, Snakegourd Fruit, Longstamen Onion Bulb.Should
Chinese medicine preparation substantially reduces the rhythm of the heart based on QI invigorating, promoting blood circulation, slit phlegm with reference to western medical treatment treatment myocardial infarction induced by myocardial ischemia
The incidence of the complication such as not normal, pump failure, embolism；Intravenous thrombolysis therapy significantly reduces hospital mortality.And for example
CN101433689A discloses a kind of kudzu root and longstamen onion bulb oral liquid, by Snakegourd Fruit, Longstamen Onion Bulb, the tuber of pinellia, the red sage root, Ligusticum wallichii, the Radix Astragali, cassia twig, wingceltis
Fragrant, fructus amomi and root of kudzu vine composition, advantage：Have no side effect, can adjust blood pressure, reducing blood lipid, blood glucose strengthen cardiac energy deposit, adjustment
Myocardial metabolism, improves human body hypoxia-bearing capability, available for heart failure adjuvant therapy, cost is low.But existing Chinese medicine preparation still can not
Improve the symptom for reversing patient's heart infarction, and wherein long-term safety sex chromosome mosaicism is still worth considering.Cardiac muscle stalk is still at present angiocarpy
Disease learns a big difficult point of Therapy study.
At present, treatment myocardial infarction medicine mainly based on western medicine, but Western medicine can only relief of symptoms, to pathology
Shortage means are treated, easily recurrence.Nearly this year comes, although all attempt to treat myocardial infarction using Chinese medicine both at home and abroad, but all not
Larger development is obtained, some Chinese medicines have certain curative effect to treatment myocardial infarction, but can not fully recover, and high recurrence rate.This
Invention aims to provide that a kind of therapeutic effect is good, the low myocardial infarction treatment medicine of toxic side effect.
The content of the invention
Big for current myocardial infarction clinical treatment poisonous side effect of medicine, the prior art that uncertain therapeutic efficacy is cut is not enough, this hair
First bright purpose is a kind of Chinese medicine composition for treating myocardial infarction of offer, and the Chinese medicine composition is in treatment myocardial infarction
Aspect has good therapeutic effect.Chinese medicine composition of the present invention, according to components by weight percent meter, including following component：Three
7 15 parts, 6 parts of akebi, 10 parts of the bark of eucommia, 10 parts of wilsonii, 10 parts of Ligusticum wallichii, 20 parts of cattail pollen, 20 parts of lotus nut, 10 parts of Poria cocos, the root of herbaceous peony 5
Part, 5 parts of ginkgo leaf, 10 parts of radix glycyrrhizae, 8 parts of the coptis, 12 parts of the root of kudzu vine, 12 parts of the root of bidentate achyranthes.Present invention Chinese medicine composition tool described above
There are a significant antiphlogistic effects, and with certain lipid-lowering effect, therefore each components matching of the Chinese medicine composition is using can be with
The effect treated both principal and secondary aspect of disease is played to myocardial infarction.
Above-mentioned Chinese medicine composition, which can be prepared into suitable pharmaceutical preparation, is used for the treatment of myocardial infarction, and the present invention is preferably
Its oral formulations, described oral formulations include mixture, tablet or capsule.
The present invention also provides a kind of preparation method of above-mentioned Chinese medicine composition, wherein described prepare Chinese medicine composition of the present invention
Method comprise the following steps：The present invention also provides a kind of method for preparing above-mentioned Chinese medicine composition, and it comprises the following steps：Claim
Each medicinal material of prescription parts by weight is taken, 7-10 times of water soaking at room temperature 10-60min for adding medicinal material gross weight is decocted after 60-90 DEG C
Boil 2-4 times, each 60-120min, filter, merging filtrate, filtrate decompression is concentrated into relative density 1.05-1.25 medicinal extract, should
Relative density is the testing result at 60 DEG C, and it is 60-90% that ethanol to alcohol content is added into medicinal extract, is stored at room temperature 24 hours
After take supernatant, reclaim ethanol to concentrating, produce Chinese medical concrete.It is described that tablet, capsule or mixture are prepared by Chinese medical concrete
Preparation technology can be made according to Chinese medicinal tablet in the prior art, capsule or mixture conventional method.This is for art technology
It is easily able to for personnel.
Invention additionally discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e., above-mentioned Chinese medicine composition is preparing myocardial infarction medicine
Purposes in thing.Creatine kinase (CK), aspartate amino transferase (AST) and lactic dehydrogenase (LDH) are to be present in the heart
Protease in myocyte, when cellular damage or necrosis, CK, AST, LDH just can be discharged into blood from intracellular, therefore survey
Determine serum CK, AST, LDH can as reflecting myocardium degree of necrosis index.Show that model group is big according to the result of this experiment table 2
CK, AST, LDH level of mouse significantly increase compared with normal group, and CK, AST, LDH level of rat are significantly reduced after administration, especially
High, normal, basic three dosage groups of Chinese medicine have pole significant difference (P ＜ 0.01) compared with model group, also have with positive controls significantly
Property (P ＜ 0.05) or pole significant difference (P ＜ 0.01).This illustrates that Chinese medicine composition of the present invention has to myocardial infarction model rat
Good therapeutic action.
In a word, the present invention compared with prior art, the activity with fine treatment myocardial infarction myocardial infarction, and can be with
The present invention is pure Chinese medicinal preparation, non-toxic particularly to liver to human body.The present invention as myocardial infarction treatment medicine in use,
Medicine effect is comprehensive, and myocardial infarction patient being made rapidly, sb.'s illness took a favorable turn；And Chinese medicine composition of the present invention is prepared simply, substantially
Nontoxic, raw material is easy to get, and is used suitable for popular, with good application prospect.
Embodiment
The present invention is further described below by way of embodiment, but the present invention is not limited only to following examples.
In the scope of the present invention or not departing from present disclosure, in spirit and scope, to Chinese medicine composition of the present invention
Be suitably modified, replace effect identical component, it will become apparent to those skilled in the art that they all by regarding
To be included within the scope of the present invention.
Part I, the preparation of Chinese medicine composition of the present invention
The Chinese medicine composition mixture of the present invention of embodiment 1
Prescription：Pseudo-ginseng 150g, akebi 60g, bark of eucommia 100g, wilsonii 100g, Ligusticum wallichii 100g, cattail pollen 200g, lotus nut 200g,
Poria cocos 100g, root of herbaceous peony 50g, ginkgo leaf 50g, radix glycyrrhizae 100g, coptis 80g, root of kudzu vine 120g, root of bidentate achyranthes 120g.
Preparation method：Each medicinal material of prescription parts by weight is weighed, 7 times of water soaking at room temperature 10min of medicinal material gross weight is added
Decocted 4 times after 60 DEG C, each 60min, filtration, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.05, the phase
It is the testing result at 60 DEG C to density, it is 60% that ethanol to alcohol content is added into medicinal extract, is taken after being stored at room temperature 24 hours
Supernatant, reclaims ethanol to concentrating, adds water to 1000ml, stir evenly, dispense, flowing steam sterilization 35min produces mixture.
The Chinese medicine composition tablet of the present invention of embodiment 2
Prescription：Pseudo-ginseng 1500g, akebi 600g, bark of eucommia 1000g, wilsonii 1000g, Ligusticum wallichii 1000g, cattail pollen 2000g, lotus
Heart 2000g, Poria cocos 1000g, root of herbaceous peony 500g, ginkgo leaf 500g, radix glycyrrhizae 1000g, coptis 800g, root of kudzu vine 1200g, root of bidentate achyranthes 1200g.
Preparation method：Each medicinal material of prescription parts by weight is weighed, 10 times of water soaking at room temperature 60min of medicinal material gross weight is added
Decocted 2 times after 90 DEG C, each 60min, filtration, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.25, the phase
It is the testing result at 60 DEG C to density, it is 90% that ethanol to alcohol content is added into medicinal extract, is taken after being stored at room temperature 24 hours
Supernatant, reclaims ethanol to concentration, vacuum drying, granulation, tabletting are produced.
The Chinese medicinal composition capsules of the present invention of embodiment 3
Prescription：Pseudo-ginseng 15kg, akebi 6kg, bark of eucommia 10kg, wilsonii 10kg, Ligusticum wallichii 10kg, cattail pollen 20kg, lotus nut 20kg,
Poria cocos 10kg, root of herbaceous peony 5kg, ginkgo leaf 5kg, radix glycyrrhizae 10kg, coptis 8kg, root of kudzu vine 12kg, root of bidentate achyranthes 12kg.
Preparation method：Each medicinal material of prescription parts by weight is weighed, 8 times of water soaking at room temperature 30min of medicinal material gross weight is added
Decocted 3 times after 60-90 DEG C, each 90min, filtration, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.15,
The relative density is the testing result at 60 DEG C, and it is 75% that ethanol to alcohol content is added into medicinal extract, is stored at room temperature 24 hours
After take supernatant, reclaim ethanol to concentrating, be dried in vacuo, granulation is encapsulated to produce.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
Influence of the present composition of embodiment 4 to myocardial infarction model rat
From body weight 230-260g male SD rats, 30mg/kg anaesthetized with pentobarbital rats are injected intraperitoneally.Back of the body position is fixed,
With more than half suction ball (size is just enclosed on rat head), with ALC-V8 type animal respirators, tidal volume 10ml/kg, breathing frequency
45~50 times/min of rate, respiratory quotient is 1: 1.Chest unhairing, sterilization, along the longitudinally slit skin 20mm of left mid-clavicular line, the 4th, 5
Intercostal blunt separation muscle layer, intercostal muscle is strutted with curved hemostat and pleura enters thoracic cavity, cuts off pericardium, and right side chest is gently pressed with middle finger
Corridor, thumb pressure xiphoid-process bottom, extrudes heart, using great cardiac vein as mark, left auricle of heart root between left auricle of heart and pulmonary conus
2~3mm of subordinate passes through coronary artery left anterior descending branch with 6-0 hurtless measures suture, and depth of needle about 0.5mm ligatures arteria coroaria sinistra
Descending anterior branch.Heart is sent back in thoracic cavity, thoracic cavity is gently extruded, thoracic cavity air is excluded, layer-by-layer suture thoracic incision closes chest.It is postoperative
The prevention infection in three days of intramuscular injection penicillin.After modeling success, gastric infusion 2 weeks, positive drug is given Carvedilol administration and terminated, greatly
Mouse is anaesthetized, and abdomen cardinal vein takes hematometry CK, AST and LDH, and testing result is shown in Table 1.
Influence of the Chinese medicine composition of the present invention of table 1 to myocardial infarction model rat
| Group | n | Dosage (mg/kg/d) | CK(U/L) | AST(U/L) | LDH(U/L) |
| Normal group | 10 | Isometric distilled water | 365±38 | 54±11 | 324±35 |
| Model group | 10 | Isometric distilled water | 1348±262▲▲ | 231±44▲▲ | 1454±331▲▲ |
| Positive controls | 10 | 10 | 904±97* | 153±32* | 965±204* |
| Low group of Chinese medicine | 10 | 200 | 658±84* | 124±29* | 859±117* |
| Group in Chinese medicine | 10 | 1000 | 549±67* △ | 86±18* △ | 734±115* △ |
| High group of Chinese medicine | 10 | 5000 | 437±57* △ | 68±14* △ | 610±98* △ |
Compared with normal group,▲▲P ＜ 0.01；Compared with model group*P ＜ 0.05,*P ＜ 0.01；With positive controls ratio
Compared with △ P ＜ 0.05.
Creatine kinase (CK), aspartate amino transferase (AST) and lactic dehydrogenase (LDH) are to be present in cardiac muscle carefully
The protease of intracellular, when cellular damage or necrosis, CK, AST, LDH just can be discharged into blood from intracellular, therefore determine blood
Clear CK, AST, LDH can as reflecting myocardium degree of necrosis index.Shown according to the result of this experiment table 2, model group rats
CK, AST, LDH level significantly increase compared with normal group, and CK, AST, LDH level of rat are significantly reduced after administration, especially Chinese medicine
High, normal, basic three dosage groups have pole significant difference (P ＜ 0.01), also there is conspicuousness (P with positive controls compared with model group
＜ 0.05) or pole significant difference (P ＜ 0.01).This illustrates that Chinese medicine composition of the present invention has very well to myocardial infarction model rat
Therapeutic action.
Claims (2)
1. a kind of Chinese medicine composition for treating or preventing myocardial infarction, it is characterised in that it is made by the raw material of following parts by weight：
15 parts of pseudo-ginseng, 6 parts of akebi, 10 parts of the bark of eucommia, 10 parts of wilsonii, 10 parts of Ligusticum wallichii, 20 parts of cattail pollen, 20 parts of lotus nut, 10 parts of Poria cocos, the root of herbaceous peony
5 parts, 5 parts of ginkgo leaf, 10 parts of radix glycyrrhizae, 8 parts of the coptis, 12 parts of the root of kudzu vine, 12 parts of the root of bidentate achyranthes；Described pharmaceutical composition is its oral formulations,
The oral formulations of described pharmaceutical composition are its mixture, tablet or capsule；
The preparation method of the Chinese medicine composition, comprises the following steps：Each medicinal material of prescription parts by weight is weighed, medicinal material gross weight is added
The water soaking at room temperature 10-60min of 7-10 times of amount is decocted 2-4 times after 60-90 DEG C, each 60-120min, filtration, merges filter
Liquid, filtrate decompression is concentrated into relative density 1.05-1.25 medicinal extract, and the relative density is the testing result at 60 DEG C, to leaching
It is 60-90% that ethanol to alcohol content is added in cream, is stored at room temperature after 24 hours and takes supernatant, reclaims ethanol to concentrating, produces.
2. Chinese medicine composition as claimed in claim 1 is preparing the purposes in treating or preventing myocardial infarction medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410471854.8A CN104189288B (en) | 2014-09-16 | 2014-09-16 | A kind of Chinese medicine composition for treating myocardial infarction and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410471854.8A CN104189288B (en) | 2014-09-16 | 2014-09-16 | A kind of Chinese medicine composition for treating myocardial infarction and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104189288A CN104189288A (en) | 2014-12-10 |
| CN104189288B true CN104189288B (en) | 2017-10-27 |
Family
ID=52074760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410471854.8A Expired - Fee Related CN104189288B (en) | 2014-09-16 | 2014-09-16 | A kind of Chinese medicine composition for treating myocardial infarction and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104189288B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311426A (en) * | 2015-11-18 | 2016-02-10 | 暨南大学 | Pharmaceutical composition containing folium artemisiae argyi for treating myocardial infarction and preparation method of pharmaceutical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634191A (en) * | 2003-12-30 | 2005-07-06 | 张琼芳 | Medicine for treating coronary heart disease and the symptoms of chest stuffiness, chest pain and heart palpitation |
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
| CN103816280A (en) * | 2014-03-25 | 2014-05-28 | 崔新明 | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
| CN103908490A (en) * | 2014-03-27 | 2014-07-09 | 杨景 | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof |
-
2014
- 2014-09-16 CN CN201410471854.8A patent/CN104189288B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634191A (en) * | 2003-12-30 | 2005-07-06 | 张琼芳 | Medicine for treating coronary heart disease and the symptoms of chest stuffiness, chest pain and heart palpitation |
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
| CN103816280A (en) * | 2014-03-25 | 2014-05-28 | 崔新明 | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
| CN103908490A (en) * | 2014-03-27 | 2014-07-09 | 杨景 | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 冠心病"虚、瘀、痰、毒"致病浅析;齐婧;《新中医》;20140630;第46卷(第6期);第259页，右栏，第13-16行 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104189288A (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| CN104126707A (en) | Atherosclerosis-conditioning tea | |
| CN102764371B (en) | Traditional Chinese medicine compound prescription for relieving radiotherapy side reactions and preparation method and application thereof | |
| CN1814162A (en) | Pulse-promoting large-volume injecta and preparing method | |
| CN103070943B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN107496573A (en) | Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN105833229A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN101450106A (en) | Traditional Chinese medicine composition with ischemic myocardium angiogenesis promoting function | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN101721638B (en) | Oral liquor for treating coronary heart disease | |
| CN100384439C (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| EP3015112B1 (en) | Medicament for treatment of hepatic ascites and preparation method therefor | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN105456684A (en) | Traditional Chinese medicine composition for Qi-Yin deficiency type atrial fibrillation and preparation method thereof | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104161800B (en) | It is a kind of to be used to treat Chinese medicine composition of angiocardiopathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Yuqing Inventor after: Zhang Zhiyu Inventor after: Yang Mingxia Inventor before: Chen Yuanzheng |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170920 Address after: 262700 two Department of heart, Shouguang people's Hospital, 1233 health Street, Shouguang, Shandong Applicant after: Zhang Yuqing Address before: 276017 Shandong, Linyi, Luozhuang District Commercial Street, No. 31 Applicant before: Chen Yuanzheng |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171027 Termination date: 20190916 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |